Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2
- 15 January 2009
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 17 (2), 731-740
- https://doi.org/10.1016/j.bmc.2008.11.049
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicansPLoS Pathogens, 2007
- AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor XenograftsCancer Research, 2006
- Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 InhibitorJournal of Medicinal Chemistry, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinaseBioorganic & Medicinal Chemistry Letters, 2005
- Bevacizumab: Antiangiogenic cancer therapyDrugs of Today, 2005
- New inhalation anaesthetics: II. Fluorinated methyl propyl ethersJournal of Fluorine Chemistry, 1978
- Effect of trifluoromethoxy, chlorodifluoromethoxy, and trifluoromethyl on the antimalarial activity of 5-benzyl- and 5-phenyl-2,4-diaminopyrimidinesJournal of Medicinal Chemistry, 1973
- General anesthetics. 3. Fluorinated methyl ethyl ethers as anesthetic agentsJournal of Medicinal Chemistry, 1972